Goldman Sachs Maintains Buy on Beta Bionics, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 48.3%

Neg 48.3% Neu 0% Pos 0%

Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $23 to $20.